相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
George R. Nahas et al.
LEUKEMIA & LYMPHOMA (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes
Andrew Shaefer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Managing the toxicities of CAR T-cell therapy
Sattva S. Neelapu
HEMATOLOGICAL ONCOLOGY (2019)
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
Jeremy S. Abramson et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
Joshua A. Hill et al.
BLOOD (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
Ronald L. Van Heertum et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy
Mahdi Shabani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy
S. Gill et al.
ANNALS OF ONCOLOGY (2010)
Abnormal immunity and stem/progenitor cells in acquired aplastic anemia
Jian Ping Li et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
分享论文
